UBE1Y1 Inhibitors
UBE1Y1 inhibitors are a class of chemical compounds that specifically target and inhibit the activity of the UBE1Y1 enzyme, which is an E1 ubiquitin-activating enzyme. UBE1Y1 plays a pivotal role in the ubiquitin-proteasome system, a biochemical pathway responsible for tagging and degrading unwanted or damaged proteins within the cell. This process begins with the activation of ubiquitin by E1 enzymes like UBE1Y1, which catalyze the ATP-dependent attachment of ubiquitin to specific target proteins, marking them for subsequent degradation by the proteasome. Inhibiting UBE1Y1 disrupts this cascade, leading to alterations in cellular protein homeostasis. By blocking the initial step of ubiquitin activation, UBE1Y1 inhibitors prevent the downstream conjugation and degradation processes, causing an accumulation of proteins that would otherwise be recycled.
Structurally, UBE1Y1 inhibitors often contain molecular frameworks designed to selectively bind the active site or allosteric regions of the UBE1Y1 enzyme, preventing its interaction with ubiquitin and ATP. The specificity of these inhibitors can vary, with some designed to precisely target UBE1Y1 without affecting other ubiquitin-activating enzymes, while others may exhibit broader inhibitory effects on related E1 enzymes. These inhibitors are also useful as tools for investigating the fundamental biological processes governed by ubiquitin-mediated protein degradation. In particular, they allow researchers to study the mechanistic roles of UBE1Y1 in cellular signaling, protein turnover, and stress responses. Furthermore, their role in modulating proteostasis makes UBE1Y1 inhibitors valuable in probing the consequences of ubiquitin system dysfunction at the molecular level.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Geldanamycin | 30562-34-6 | sc-200617B sc-200617C sc-200617 sc-200617A | 100 µg 500 µg 1 mg 5 mg | $38.00 $58.00 $102.00 $202.00 | 8 | |
Geldanamycin inhibits the expression of ubiquitin-activating enzyme, Chr Y by binding to Hsp90, leading to the degradation of Hsp90 client proteins including the enzyme, through the ubiquitin-proteasome pathway. | ||||||
17-AAG | 75747-14-7 | sc-200641 sc-200641A | 1 mg 5 mg | $66.00 $153.00 | 16 | |
17-AAG inhibits the expression of ubiquitin-activating enzyme, Chr Y by binding to Hsp90, causing destabilization and degradation of Hsp90 client proteins including the enzyme, via the ubiquitin-proteasome pathway. | ||||||
Radicicol | 12772-57-5 | sc-200620 sc-200620A | 1 mg 5 mg | $90.00 $326.00 | 13 | |
Radicicol inhibits the expression of ubiquitin-activating enzyme, Chr Y by binding to Hsp90, leading to the destabilization and degradation of Hsp90 client proteins including the enzyme, via the ubiquitin-proteasome pathway. | ||||||
NVP-AUY922 | 747412-49-3 | sc-364551 sc-364551A sc-364551B sc-364551C sc-364551D sc-364551E | 5 mg 25 mg 100 mg 250 mg 1 g 5 g | $150.00 $263.00 $726.00 $1400.00 $2900.00 $11000.00 | 3 | |
NVP-AUY922 inhibits the expression of ubiquitin-activating enzyme, Chr Y by binding to Hsp90, causing destabilization and degradation of Hsp90 client proteins including the enzyme, via the ubiquitin-proteasome pathway. | ||||||
BIIB 021 | 848695-25-0 | sc-364434 sc-364434A | 5 mg 25 mg | $128.00 $650.00 | ||
BIIB021 inhibits the expression of ubiquitin-activating enzyme, Chr Y by binding to Hsp90, leading to the destabilization and degradation of Hsp90 client proteins including the enzyme, through the ubiquitin-proteasome pathway. | ||||||
SAG | 912545-86-9 | sc-212905 sc-212905A | 1 mg 5 mg | $163.00 $413.00 | 27 | |
AT13387 inhibits the expression of ubiquitin-activating enzyme, Chr Y by binding to Hsp90, causing destabilization and degradation of Hsp90 client proteins including the enzyme, via the ubiquitin-proteasome pathway. | ||||||
Ganetespib | 888216-25-9 | sc-364496 sc-364496A | 10 mg 250 mg | $268.00 $1020.00 | ||
Ganetespib inhibits the expression of ubiquitin-activating enzyme, Chr Y by binding to Hsp90, leading to the destabilization and degradation of Hsp90 client proteins including the enzyme, through the ubiquitin-proteasome pathway. | ||||||
17-DMAG | 467214-20-6 | sc-202005 | 1 mg | $201.00 | 8 | |
Alvespimycin inhibits the expression of ubiquitin-activating enzyme, Chr Y by binding to Hsp90, leading to the destabilization and degradation of Hsp90 client proteins including the enzyme, via the ubiquitin-proteasome pathway. | ||||||